進行性悪性腫瘍患者におけるLAG525単剤療法およびPDR001との併用療法の安全性と有効性。

基本情報

NCT ID: NCT02460224
ステータス: 完了
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 490
治験依頼者名: Novartis

概要

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation (phase 1) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion (phase 2) which characterized treatment of LAG525 in combination with PDR001 at the MTD or RP2D.

対象疾患

Advanced Solid Tumors

介入

LAG525(DRUG)

PDR001(DRUG)

依頼者（Sponsor）

ノバルティスファーマ株式会社(INDUSTRY)